

CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED

(Formerly known as Albedo Limited)

(Company Registration No. 200505118M)

INCORPORATION OF JOINT VENTURE COMPANIES

The Board of Directors (the “**Board**”) of China Medical (International) Group Limited (the “**Company**”) and together with its subsidiaries, the “**Group**”) refers to the Company’s announcement dated 18 August 2016 in relation to the execution of the joint venture agreements dated 17 August 2016 between CMIG Medical Services (Hong Kong) Limited (“**CMIGMS**”), a wholly-owned subsidiary of the Company and Dr Yan Hai and Dr Qin Hong (collectively, “**Drs**”) and Gen Young Aesthetic Medical Management Consultancy Limited (“**GY**”). Both Drs and GY are independent of the Group. Unless otherwise defined, capitalised terms herein shall have the same meanings as those defined in the announcement of the Company dated 18 August 2016.

The Board wishes to update the Company’s shareholders that the Joint Venture Companies have been incorporated in the Hong Kong Special Administrative Region of the People’s Republic of China on 30 August 2016.

Details of the Joint Venture Companies

1. CMIG Ren Feng Medical (Futian) Limited has an initial issued and paid-up capital of HK\$1,736,395.00 divided into 10,000 shares with CMIGMS, Dr Yan and Dr Qin holding 5,000 shares (50%), 2,500 shares (25%) and 2,500 shares (25%) respectively. The principal business activity is investment holding and the first directors of CMIG Ren Feng Medical (Futian) Limited are Mr Tai Kok Chuan, Mr Tan Kai Teck, Mr Tan Giong Seng, Johnson, Dr Yan Hai and Dr Qin Hong.
2. CMIG Ren Feng Medical (Nanshan) Limited has an initial issued and paid-up capital of HK\$10,000.00 divided into 10,000 shares with CMIGMS, Dr Yan and Dr Qin holding 5,000 shares (50%), 2,500 shares (25%) and 2,500 shares (25%) respectively. The principal business activity is investment holding and the first directors of CMIG Ren Feng Medical (Nanshan) Limited are Mr Tai Kok Chuan, Mr Tan Kai Teck, Mr Tan Giong Seng, Johnson, Dr Yan Hai and Dr Qin Hong.
3. CMIG Ren Feng Med-Biotechnology Limited has an initial issued and paid-up capital of HK\$10,000.00 divided into 10,000 shares with CMIGMS, Dr Yan and Dr Qin holding 5,000 shares (50%), 2,500 shares (25%) and 2,500 shares (25%) respectively. The principal business activity is investment holding and the first directors of CMIG Ren Feng Med-Biotechnology Limited are Mr Tai Kok Chuan, Mr Tan Kai Teck, Mr Tan Giong Seng, Johnson, Dr Yan Hai and Dr Qin Hong.
4. CMIG GY Sales Limited has an initial issued and paid-up capital of HK\$100.00 divided into 100 shares with CMIGMS and GY holding 51 shares (51%) and 49 shares (49%) respectively. The principal business activity is investment holding and the first directors of CMIG GY Sales Limited are Mr Tai Kok Chuan, Mr Tan Kai Teck, Mr Tan Giong Seng, Johnson, Mr Chung Ping Nan and Ms Shih Lei Lei.

The incorporation of the Joint Venture Companies had been funded through internal resources of the Group and is not expected to have any material impact on the earnings per share or net tangible assets per share of the Group for the current financial year ending 31 December 2016.

Save as disclosed above, and as far as the Company is aware, none of the Directors or controlling shareholders of the Company, as well as their respective associates, has any interest, direct or indirect, in the abovementioned transactions (other than through their interests in the shares of the Company).

The Company will update shareholders in due course if there are further material developments in connection with the Joint Venture Companies.

BY ORDER OF THE BOARD

30 August 2016

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Director, Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.